Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 12/20 | 0.50 |
| ▸ | HTR3A | P46098 | 3/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.34 |
| ▸ | KIF11 | P52732 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19271788 | 0.79 | EPHX2 (0.44) | EPHX2HTR3AKCNA5 | |
| SCHEMBL24109188 | 0.77 | EPHX2 (0.40) | EPHX2HTR3AKIF11 | |
| SCHEMBL12011578 | 0.77 | CHRNB2 (0.41) | EPHX2KIF11 | |
| SCHEMBL15108909 | 0.77 | CHRNA7 (0.51) | EPHX2HTR3ACHRNA7 | |
| SCHEMBL25595703 | 0.76 | EPHX2 (0.38) | EPHX2KCNA5KIF11 | |
| SCHEMBL1690350 | 0.76 | F9 (0.43) | EPHX2KIF11 | |
| SCHEMBL26633206 | 0.76 | EPHX2 (0.39) | EPHX2HTR3ACHRNA7 | |
| SCHEMBL23478968 | 0.76 | ALDH1A1 (0.39) | EPHX2KIF11 | |
| SCHEMBL14572005 | 0.76 | ALDH1A1 (0.42) | EPHX2KIF11 | |
| SCHEMBL18590267 | 0.73 | GRM4 (0.40) | EPHX2KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-01-06 | — | — | US | disclosed |
| US-11136321-B2 | Tricyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000874-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | EPHX2 2436/4885HTR3A 1407/4885KCNA5 1975/4885 |
| US-11136321-B2 | Tricyclic compounds | SLC10A1, PKD1, CEL | EPHX2 2436/4885HTR3A 1407/4885KCNA5 1975/4885 |
| US-20200407361-A1 | TRICYCLIC COMPOUNDS | SLC10A1, PKD1, CEL | EPHX2 2436/4885HTR3A 1407/4885KCNA5 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.